Alaunos Therapeutics Inc (TCRT)
2.13
+0.12
(+6.01%)
USD |
NASDAQ |
Nov 05, 11:30
Alaunos Therapeutics Research and Development Expense (Annual): 16.28M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 16.28M |
| December 31, 2022 | 25.02M |
| December 31, 2021 | 49.64M |
| December 31, 2020 | 52.70M |
| December 31, 2019 | 38.33M |
| December 31, 2018 | 34.13M |
| December 31, 2017 | 45.08M |
| December 31, 2016 | 157.79M |
| December 31, 2015 | 106.78M |
| December 31, 2014 | 32.71M |
| Date | Value |
|---|---|
| December 31, 2013 | 42.85M |
| December 31, 2012 | 83.45M |
| December 31, 2011 | 57.08M |
| December 31, 2010 | 12.91M |
| December 31, 2009 | 4.556M |
| December 31, 2008 | 17.24M |
| December 31, 2007 | 18.99M |
| December 31, 2006 | 10.39M |
| December 31, 2005 | 5.594M |
| December 31, 2004 | 2.127M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
16.28M
Minimum
2023
52.70M
Maximum
2020
36.39M
Average
38.33M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.31M |
| Oragenics Inc | 15.49M |
| Cocrystal Pharma Inc | 15.17M |
| Cara Therapeutics Inc | 108.51M |
| Jaguar Health Inc | 18.60M |